Development of brain penetrant TTBK1 and TTBK2 inhibitors may also provide a viable strategy for intervening in TDP-43 proteinopathy disorders including ALS and FTLD-TDP. Here, TTBK1 is linked to amyotrophic lateral sclerosis.